11.09.20 -- New Podcast Episodes: CAR T Therapy Cost Control, Gap Analysis, And More

Check out the latest from Business of Biotech, Biotech with the Bozenhardts, and Life Science Connect. As a member of the Life Science Connect community you have access to content beyond our weekly newsletters, including our podcast series. Don’t forget to subscribe so that you never miss an episode!

Find out what drove John McKearn, Ph.D. and CEO at Wugen, out of the lab at Pfizer and on to his quest to develop off-the-shelf cell therapies for T-cell leukemias and lymphomas, acute myeloid leukemia, and multiple myeloma.

Controlling the cost of personalized medicine: We go behind the scenes of the effort to build a system that simplifies production and reduces the cost of nonviral T-cell therapies with Ziopharm Oncology CEO Laurence Cooper, M.D., Ph.D.

We're joined by biopharma pioneer Dr. Pablo Valenzuela and rising star Cristián Hernández-Cuevas, both of Andes Biotechnologies, for a candid discussion on biopharma's compute power revolution, gap analyses, next steps for emerging biopharma, and what's driving growth in South America.

Herman and Erich Bozenhardt have a collective 55 years of bioprocess facilities design and equipment experience, and they’re here to share it all in our fresh Bioprocess with the Bozenhardts podcast series.

It was only a little more than a year ago when the phrase “throw in the towel” was being used in reference to the biosimilars industry. Now, some say we’re in the “golden age” of biosimilars. Anna Rose Welch tries to explain why the big flip. 

Our guest, Outsourced Pharma chief editor Louis Garguilo, talks about the response from readers — and PhRMA — to his editorial, “Is PhRMA’s White House Rebuttal Acceptable?”